Pathophysiology of vascular endothelium and circulating platelets: Implications for coronary revascularisation and treatment

International Journal of Cardiology

Volumn 79, Issue 2-3, 2001, Pages 265-275

  Amoroso, Giovanni ^a   Van Veldhuisen, Dirk J ^a   Tio, René A ^a   Mariani, Mario ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Coronary revascularisation; Endothelium; Platelets

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIOXIDANT; ARGININE; ASCORBIC ACID; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPTIFIBATIDE; LISINOPRIL; MEVINOLIN; PRAVASTATIN; PROBUCOL; QUINAPRIL; SIMVASTATIN; TICLOPIDINE; TIROFIBAN;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CARDIOVASCULAR SURGERY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; DIAGNOSTIC VALUE; DISEASE COURSE; ENDOTHELIUM INJURY; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HUMAN; NON INVASIVE MEASUREMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

EID: 0034925054     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(01)00448-X     Document Type: Article

References (82)

1. Regulatory functions of the vascular endothelium
2. Molecular and cellular mechanism of endothelin regulation
3. Endothelial dysfunction: From physiology to therapy
4. Normal endothelial cell function
5. Inhibitory role of the endothelium in the response of isolated coronary arteries to platelets
6. Endothelial dysfunction: The role and impact of the renin-angiotensin system
7. Endothelial cell function and thrombosis
8. Endothelial adhesion molecules in health and disease
9. Regulation of smooth muscle cell growth by endothelium-derived factors
10. The endothelium in atherogenesis
11. Atherogenesis: Current understanding of the cause of atheroma
12. Low density lipoprotein oxidation and its pathobiological significance
13. The pathogenesis of atherosclerosis: A perspective for the 1990s
14. Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease
15. Endothelial dysfunction, hemodynamic forces, and atherogenesis
16. Redistribution of von Willebrand factor in porcine carotid arteries after balloon angioplasty
17. Expression of endothelial factors after arterial injury in the rat
18. Natural course of the impairment of endothelium-dependent relaxations after balloon endothelium removal in porcine coronary arteries
19. Morphology of the endothelium over atherosclerotic plaques in human coronary arteries
20. Abnormal vasomotor changes early after coronary angioplasty. A quantitative arteriographic study of their time course
21. Coronary vasoconstriction in response to acetylcholine after balloon angioplasty: Possible role of endothelial dysfunction
22. Response of human coronary arteries to serotonin after injury by coronary angioplasty
23. Long-term endothelial dysfunction is more pronounced after stenting than after balloon angioplasty in porcine coronary arteries
24. Long-term endothelial dysfunction after coronary artery stenting
25. Evidence for altered epicardial coronary artery autoregulation as a cause of distal coronary vasoconstriction after successful percutaneous transluminal coronary angioplasty
26. Normalization of coronary vasomotion after percutaneous transluminal coronary angioplasty?
27. Effect of percutaneous transluminal coronary angioplasty on circulating endothelin levels
28. Basic cellular mechanisms of coronary bypass graft disease
29. Different activation of endothelial L-arginine and cyclooxygenase pathway in human internal mammary artery and saphenous vein
30. Effect of acetylcholine on arterial and venous grafts and coronary arteries in patients with coronary artery disease
31. Endothelium-dependent and endothelium-independent flow regulation in coronary vascular regions supplied by arterial and venous bypass grafts
32. Internal mammary coronary artery grafts: Is their superiority also due to a basically intact endothelium?
33. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease
34. Role of nitric oxide in coronary arterial vasomotion and the influence of coronary atherosclerosis and its risks
35. Angiographic assessment of human coronary artery endothelial function by measurement of endothelium-dependent vasodilation
36. The assessment of endothelial function in the cardiac catheterization laboratory in patients with risk factors for atherosclerotic coronary artery disease
37. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
38. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries
39. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease
40. Influence of radiographic contrast agents on quantitative coronary angiography
41. Assessment of endothelial modulation of coronary vasomotor tone: Insights into a fundamental functional disturbance in vascular biology of atherosclerosis
42. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction
43. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary artery disease
44. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy
45. Effect of endothelial dysfunction on regional perfusion in myocardial territories supplied by normal and diseased vessels in patients with coronary artery disease
46. Clinical implications of endothelial dysfunction
47. Intensive lifestyle changes for reversal of coronary heart disease
48. Correcting endothelial dysfunction in coronary microcirculation of hypercholesterolemic patients by L-arginine
49. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease
50. Influence of smoking status on progression of endothelial dysfunction. TREND investigators. Trial on reversing endothelial dysfunction
51. Importance of endothelial function in mediating the benefits of lipid-lowering therapy
52. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia
53. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
54. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion
55. Simvastatin, an HMG-CoA reductase inhibitor, improves endothelial function within 1 month
56. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: The TREND (Trial on Reversing Endothelial Dysfunction) study
57. Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition: A potential role of bradykinin
58. Lisinopril improves arterial function in hyperlipidaemia
59. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease
60. Platelet surface activation antigen expression at baseline and during elective angioplasty in patients with mild to moderate coronary artery disease
61. Role of platelet-endothelial cell adhesion molecule (PECAM) in platelet adhesion/aggregation over injured but not denuded endothelium in vivo and ex vivo
62. Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells
63. Evaluation of platelet membrane glycoproteins in coronary artery disease. Consequences for diagnosis and therapy
64. Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty
65. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty
66. Role of platelet membrane glycoproteins and von Willebrand factor in adhesion of platelets to subendothelium and collagen
67. Role of platelet inhibitor agents in coronary artery disease
68. Arterial response to mechanical injury: Balloon catheter de-endothelialization
69. Acute and chronic tissue response to coronary stent implantation: Pathologic findings in human specimen
70. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty
71. Different interactions of platelets with arterial and venous coronary bypass vessels
72. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty
73. Results of a consecutive series of patients receiving only antiplatelet therapy after optimised stent implantation. Comparison of aspirin alone versus combined ticlopidine and aspirin therapy
74. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance
75. Clopidogrel and coronary stenting: What is the next question?
76. IIb's are not IIb's
77. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularisation
78. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary coronary angioplasty
79. Evaluation of platelet IIb/IIIa inhibitor for stenting. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
80. Highlights from the XXII Congress of the European Society of Cardiology: August 26-30, 2000
81. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy
82. Enhanced suppression of the platelet IIb/IIIa receptor with integrilin therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial